MEI PharmaMEIP
Market Cap: $19.3M
About: MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Employees: 46
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,700% more call options, than puts
Call options by funds: $56K | Put options by funds: $2K
2.36% less ownership
Funds ownership: 43.34% [Q1] → 40.97% (-2.36%) [Q2]
3% less funds holding
Funds holding: 32 [Q1] → 31 (-1) [Q2]
31% less capital invested
Capital invested by funds: $11.5M [Q1] → $7.94M (-$3.58M) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for MEIP.